Skip to main content
SpringerLink
Log in

Therapie des Typ-2-Diabetes

Welchen Stellenwert haben SGLT-2-Blocker?

  • FORTBILDUNG_SEMINAR
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Mit der Progression eines Typ-2-Diabetes mellitus wird in aller Regel eine Therapieeskalation notwendig, da trotz antihyperglykämischer Behandlung die HbA1c-Werte wieder ansteigen. Die Entwicklung neuer Substanzgruppen in den letzten Jahren bedeutet daher eine Bereicherung unserer Therapieoptionen. Wie SGLT-2-Blocker wirken und für welche Patienten sie empfehlenswert sind, erfahren Sie im nachfolgenden Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1:

Literatur

  1. Berthold HK, Gouni-Berthold I, Bestehorn K et al. Kardiovaskuläre Risikofaktoren bei Typ2-Diabetikern in Deutschland — ein Versorgungsparadox. Dtsch Ärztebl 2007; 104:A861–867

    Google Scholar 

  2. Huppertz E, Pieper I, Klotsche J et al. Diabetes mellitus in German primary care: Quality of glycemic control and subpopulations not well controlled — results of the DETECT Study. Exp Clin Endocrinol Diabetes 2009; 117:6–14

    Article  CAS  PubMed  Google Scholar 

  3. Storgaard H et al. 74th ADA Annual Meeting 2014, San Francisco, USA: 1107-P

  4. Nauck MA, DelPrato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active- controlled noninferiority trial. Diabetes Care 2011; 34:2015–2022

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Rosenwasser RF, Sultan S, Sutton D et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metabol Syndrome and Obesity 2013; 6:453–467

    CAS  Google Scholar 

  6. Musso G, Gambino R, Cassander M et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44:375–393

    Article  CAS  PubMed  Google Scholar 

  7. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagloflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97:1020–1031

    Article  CAS  PubMed  Google Scholar 

  8. Hach T, Lambers Heerspink H, Pfarr E et al. The SGLT-2 inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes (poster 65). Preceedings of the 4th world congress on controversies in diabetes, obesity and hypertension (CODHy), November 8-11, 2012, Barcelona, Spain

  9. Foote C, Perkovic V, Neal B. Effects of SGLT-2 inhibitors on cardiovascular outcomes. Diabetes Vasc Dis Res 2012; 9:117–123

    Article  Google Scholar 

  10. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metabol 2014; 16:1016–1027

    Article  Google Scholar 

  11. Barnett AH, Mithal A, Manassie J et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2:369–384

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Med. Klinik V, Nephrologie, Angiologie, Rheumatologie Klinikum Bayreuth GmbH, Preuschwitzer Straße 101, D-95445, Bayreuth, Deutschland

    Harald Rupprecht

Authors
  1. Harald Rupprecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harald Rupprecht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rupprecht, H. Welchen Stellenwert haben SGLT-2-Blocker?. MMW - Fortschritte der Medizin 157, 55–60 (2015). https://doi.org/10.1007/s15006-015-2590-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-2590-8

Keywords - The role of SGLT-2 inhibitors in the treatment of type 2 diabetes

Search

Navigation